Clinical trials: Psychosis, open to volunteers
Clinical High Risk for Psychosis (CHR), Suicidal Ideation
Developing a Recovery-Oriented Suicide Prevention Program for Young People at Clinical High Risk for Psychosis
Young people at clinical high risk for psychosis are more likely to experience suicide thoughts than the general population, but there are few suicide prevention programs designed specifically for them.
- Conditions
- Clinical High Risk for Psychosis (CHR), Suicidal Ideation, Psychosis, Suicidal Behavior
- Trial name
- NCT07756567
- Testing
- Suicide Prevention Intervention, Standard Care (in control arm)
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- University of California, San Diego
Alzheimer's Disease Psychosis
ACP-204 in Adults With Alzheimer's Disease Psychosis
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP Substudy 1 (Phase 2) will evaluate efficacy and dose…
- Trial name
- NCT06159673
- Testing
- ACP-204
- Where
- 154 sites in United States, Brazil and 10 more
- Volunteers
- 1,074 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP)
French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls
The goal of this study is to learn whether people living with severe psychiatric disorders can be grouped into more homogeneous subgroups, across usual diagnostic categories, based on two key dimensions: social withdrawal and…
- Conditions
- Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP), Bipolar Disorder (BD), Major Depressive Disorder (MDD
- Trial name
- FRENCH-MINDS (NCT07881016)
- Testing
- 3T Brain MRI, Biological Sampling, Clinical, Cognitive and Digital Assessments
- Where
- 17 sites in France
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fondation FondaMental
Psychosis Associated With Alzheimer's Disease
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056.
- Trial name
- NCT05980949
- Testing
- KarXT
- Where
- 432 sites in United States, Argentina and 29 more
- Volunteers
- 1,000 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Psychosis Associated With Alzheimer's Disease
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's…
- Trial name
- NCT06126224
- Testing
- KarXT
- Where
- 157 sites in United States, Belgium and 12 more
- Volunteers
- 500 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Schizophenia Disorder, Severe Mental Illness
Effect of Occupational Therapy on Psychosocial Parameters and Functioning in Individuals With Severe Mental Illness
Severe mental illness (SMI), including schizophrenia spectrum disorders and bipolar disorder, is associated with significant impairments in psychosocial functioning, daily life participation, self-efficacy, and social…
- Conditions
- Schizophenia Disorder, Severe Mental Illness, Bipolar Disorder, Nonorganic Psychosis
- Trial name
- OT-SMI (NCT07879118)
- Testing
- Occupational Therapy Group Intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Biruni University
Schizophrenia, Clinical High Risk for Psychosis (CHR)
Mobile Thinking Intervention: A Inital Test
This study will test the inital efficacy of a brief mobile intervention targeting biased thinking.
- Trial name
- NCT06909422
- Testing
- Mobile Intervention for Biased Thinking
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Alabama at Birmingham
Schizophrenia Prodromal, SCHIZOPHRENIA 1 (Disorder)
Online Intervention To Improve Motivation
Participants will complete one online intervention lasting 12 weeks. Each week, they will be asked to complete a 20-30 minute session online.
- Conditions
- Schizophrenia Prodromal, SCHIZOPHRENIA 1 (Disorder), Psychosis
- Trial name
- Online Mot (NCT07157293)
- Testing
- Online Motivation Enhancing Intervention
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Alabama at Birmingham
Psychosis, Suicide
Targeting Emotion Dysregulation to Reduce Suicide in People With Psychosis
People with psychotic disorders are excluded from most suicide-focused clinical trials despite incredibly high rates of completed suicide, and interventions that have been tested for this population have shown limited impact on…
- Trial name
- NCT05440214
- Testing
- Dialectical Behavior Therapy Skills Training
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Maryland, Baltimore
Sleep, Physical Activity
On Track for Wellness (OTW) Stepped Wedge Cluster Randomized Trial
This study will evaluate a program called On Track for Wellness (OTW) which is being adopted by the Illinois Department of Human Services' Division of Behavioral Health \& Recovery (DBHR) for use in all state-funded early…
- Conditions
- Sleep, Physical Activity, First Episode Psychosis
- Trial name
- OTW (NCT07387705)
- Testing
- On Track for Wellness
- Where
- United States
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Chicago
Schizophrenia; Psychosis
Feasibility Trial of a Parent Peer-Co-Led Caregiver Group for Pediatric Early Onset Schizophrenia Spectrum Disorders
While early onset schizophrenia spectrum disorders are among the most debilitating psychiatric illnesses, evidence-based treatment for this population is limited.
- Trial name
- NCT07867964
- Testing
- Group Therapy, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Boston Children's Hospital
Schizophrenia, Schizo Affective Disorder
iTBS to Enhance Social Cognition in People With Psychosis
The goal of this clinical trial is to examine if iTBS applied to the DMPFC improves social cognitive performance compared to sham stimulation in people diagnosed with schizophrenia, schizoaffective disorder, schizophreniform…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Psychosis Nos/Other
- Trial name
- iSCIP (NCT06118268)
- Testing
- iTBS (Active)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Northwell Health
Psychosis, First Episode Psychosis
Stratification and Treatment in Early Psychosis Study - ENHANCE
The purpose of this study is: To investigate whether the response to antipsychotic treatment can be enhanced by adding cannabidiol (CBD) to the existing treatment, compared to placebo, in participants with a first episode of…
- Conditions
- Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode
- Trial name
- STEP-ENHANCE (NCT06778564)
- Testing
- CBD 100 mg/mL Oral Solution
- Where
- 17 sites in Austria, Germany and 7 more
- Volunteers
- 250 people
- Sponsor
- University of Oxford
Treatment Resistant Psychosis, Psychosis
Stratification and Treatment in Early Psychosis Study -ASSIST
The purpose of this trial is: To investigate whether the response to clozapine treatment can be enhanced by adding cannabidiol (CBD), compared to placebo, in treatment resistant psychosis patients.
- Trial name
- STEP-ASSIST (NCT07326124)
- Testing
- CBD 100 mg/mL Oral Solution, Placeb
- Where
- 15 sites in Germany, Greece and 6 more
- Volunteers
- 250 people
- Sponsor
- University of Oxford
Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis
Stratification and Treatment in Early Psychosis Study - PROMOTE
The purpose of this trial is: To investigate whether cannabidiol (CBD), compared to placebo, can reduce the severity of attenuated psychotic symptoms in individuals at clinical high risk for psychosis.
- Conditions
- Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis
- Trial name
- STEP-PROMOTE (NCT07434973)
- Testing
- Cannabidiol (CBD)
- Where
- 19 sites in Austria, Canada and 8 more
- Volunteers
- 586 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Bipolar Disorder (BD), Psychosis
Multimodal Intervention to Support Hospital-to-Community Transition in Bipolar Disorder
People with bipolar disorder (BD) are at high risk of relapse following hospital discharge, partly due to a lack of BD-specific expertise and resources within community services required for comprehensive treatment.
- Trial name
- BTBD (NCT07213492)
- Testing
- Group-Based Psychoeducation, Peer Support, Personalized Support for Community Healthcare Provider
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McMaster University
Psychosis, Anxiety
Pilot Study of Sensor-Informed Smartphone-based Mental Health Interventions for Mood in Early Psychosis
The aim of this trial is to evaluate the feasibility and preliminary efficacy of using passive smartphone sensors to detect moments of heightened negative mood and inform the timing of brief mental health interventions, such as…
- Conditions
- Psychosis, Anxiety, Depression, Rumination
- Trial name
- NCT07503093
- Testing
- Smartphone-based Mindfulness Exercise, Smartphone-based Psychoeducation, Neutral Control Message
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mclean Hospital
Schizo-affective Disorder, Non Organic Psychosis
Motivational Intervention for Patients With Schizophrenia
The goal of this clinical trial is to learn if a group therapy called the Positive Emotions Program for Schizophrenia (PEPS) can reduce apathy in adults aged 18 to 60 who have schizophrenia or a related psychotic disorder.
- Conditions
- Schizo-affective Disorder, Non Organic Psychosis, Schizophenia Disorder
- Trial name
- NCT07853079
- Testing
- Positive Emotion Program for Schizophrenia (PEPS), a psychotherapeutic intervention,
- Volunteers
- 88 people
- Sponsor
- University of Geneva, Switzerland
Psychosis Associated With Alzheimer's Disease
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated…
- Trial name
- NCT06887192
- Testing
- ML-007C-MA
- Where
- 62 sites in United States, Argentina and 13 more
- Volunteers
- 300 people
- Sponsor
- MapLight Therapeutics
Lewy Body Dementia Psychosis
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
- Trial name
- NCT07029581
- Testing
- ACP-204
- Where
- 61 sites in United States, Bulgaria and 4 more
- Volunteers
- 180 people
- Sponsor
- ACADIA Pharmaceuticals Inc.